Leukemic stem cells: identification and clinical application

Hanekamp, Diana; Cloos, Jacqueline; Schuurhuis, Gerrit Jan

doi:10.1007/s12185-017-2221-5

Cited by 95 publications

(77 citation statements)

References 100 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At diagnosis and within the fraction of residual cells at follow‐up, aberrant cell surface marker expression can be used to discriminate LSCs from HSCs. Using such specific leukemia associated LSC immunophenotypes enables detection of LSCs in the vast majority of CD34 positive AML cases (Hanekamp, Cloos, & Schuurhuis, ). LSCs, as defined as aberrant marker positive CD34+CD38− cells, harbor specific molecular aberrancies (e.g., FLT3‐ITD, NPM1 mut ) and thus are indeed leukemic cells (Kersten et al., ; Schuurhuis et al., ; Terwijn et al., ).…”

Section: Commentarymentioning

confidence: 99%

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia

2019

Self Cite

View full text Add to dashboard Cite

Half of the patients with acute myeloid leukemia (AML), who achieve complete remission after chemotherapy treatment, will ultimately experience a relapse. Measurable residual disease (MRD) is an important post‐treatment risk factor in AML, because it gives additional information about the depth of the remission. Within MRD, the small population of leukemic stem cells (LSCs) is thought to be at the base of the actual relapse. In this protocol, the flow cytometric detection of MRD and LSCs herein is outlined. We give a detailed overview of the sampling procedures for optimal multiparameter flow cytometry assessment of both MRD and LSC, using leukemia associated immunophenotypes (LAIPs) and LSC markers. Moreover, an overview of the gating strategies to detect LAIPs and LSC markers is provided. This protocol serves as guidance for flow cytometric detection of measurable residual (stem cell) disease necessary for proper therapeutic decision making in AML patients. © 2019 The Authors. Basic Protocol 1: Immunophenotypic LAIP detection for measurable residual disease monitoring Basic Protocol 2: Immunophenotypic detection of CD34+CD38− leukemic stem cells

show abstract

Section: Commentarymentioning

confidence: 99%

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Caractérisées entre autre par leur quiescence, les CSL constituent une population cellulaire responsable de résistances thérapeutiques et de rechutes de la maladie chez les patients atteints de leucémie. C'est la raison pour laquelle elles sont devenues la cible de nouvelles thérapies visant à favoriser leur différenciation [1][2][3][4][5]. Suite aux observations que miR126 et GSK3 sont deux facteurs participant à la régulation du cycle cellulaire dans les CSL, des recherches se sont concentrées sur l'identification et le développement d'inhibiteurs de ces molécules [2, [6][7][8]10].…”

Section: Resultsunclassified

Cellules souches leucémiques

Bellina

2019

Med Sci (Paris)

View full text Add to dashboard Cite

show abstract

“…Chemotherapy is the most common treatment for tumors, but tumor cells can readily develop drug resistance, which is one of the important factors leading to the failure of this treatment . As there are various cell subtypes that have important effects on tumor proliferation, invasion, migration, drug resistance, and recurrence, subtypes those that are resistant to chemical drugs can survive during chemotherapy treatment . Under certain conditions these drug‐resistant cells develop into mature tumor cells, so that the chemotherapy‐resistant heterogeneous cells become enriched and more malignant.…”

Section: Introductionmentioning

confidence: 99%

Fluorescent Polysaccharide Nanogels for the Detection of Tumor Heterogeneity in Drug‐Surviving Cancer Cells

Wang

Zhang

et al. 2019

Adv. Biosys.

View full text Add to dashboard Cite

Tumor metastasis, recurrence, and drug resistance have been associated with tumor heterogeneity, and thus the identification of tumor heterogeneity has great significance in medicine. The approach provides a way to identify and isolate various cell subtypes from drug‐surviving ovarian cancer cells, by synthesizing a series of polysaccharide nanogels and using them in flow cytometry analysis. The results show that the drug‐surviving OVCAR‐3 cells that are subjected to paclitaxel intervention comprise various cell subtypes, including drug‐resistant and non‐drug‐resistant cell subtypes. Besides, there are significant differences between the drug‐resistant cell subtype and non‐drug‐resistant cell subtype in terms of their migration and invasion behavior. In addition, the phenotype switch genes are detected by mRNA sequencing, and it is found that different subtypes show significant genetic differences with regard to their drug resistance, metastasis, and proliferation. In particular, modifying polysaccharide nanogels with lipids can promote the uptake of nanogels by drug‐resistant cells, and thus the lipid modification can enhance the effectiveness of a chemotherapy drug carrier against drug‐resistant cells. These studies reveal the heterogeneity of drug‐surviving tumor cells, as well as the significant differences in drug‐resistance, migration, and invasion capabilities of different subtypes, and demonstrate a way to overcome drug resistance.

show abstract

Leukemic stem cells: identification and clinical application

Cited by 95 publications

References 100 publications

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia

Cellules souches leucémiques

Fluorescent Polysaccharide Nanogels for the Detection of Tumor Heterogeneity in Drug‐Surviving Cancer Cells

Contact Info

Product

Resources

About